Biofrontera AG (BFRA) News

Biofrontera AG (BFRA): $2.67

0.28 (-9.49%)

POWR Rating

Component Grades








Add BFRA to Watchlist
Sign Up

Filter BFRA News Items

BFRA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BFRA News Highlights

  • For BFRA, its 30 day story count is now at 5.
  • Over the past 13 days, the trend for BFRA's stories per day has been choppy and unclear. It has oscillated between 2 and 3.
  • The most mentioned tickers in articles about BFRA are BFRI, ADM and ADS.

Latest BFRA News From Around the Web

Below are the latest news stories about Biofrontera AG that investors may wish to consider to help them evaluate BFRA as an investment opportunity.

Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs

Leverkusen, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera AG (the “Company”) (Nasdaq: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, decided today its American Depositary Shares (“ADS”) should be delisted from the Nasdaq Capital Market (“Nasdaq”) and its reporting obligations with the Securities and Exchange Commission (“SEC”) should be deregistered and terminated. The main purpose of the delisting is to reduce complexity in financial reporting and adm

Yahoo | February 14, 2022

Biofrontera Stock Plunges After Announcing Nasdaq Delisting

By Sam Boughedda

Yahoo | February 14, 2022

Why Are Biofrontera Shares Rising Today?

Biofrontera Inc (NASDAQ: BFRI ) has provided an update on the patient recruitment for the Phase 3 study for superficial basal cell carcinoma (sBCC) with Ameluz photodynamic therapy (PDT) combined with BF-RhodoLED lamp in the U.S. To date, 70% of the planned 186 patients have been enrolled in the study. Patient recruitment for this study has been ongoing since 2018, with the Full story available on

Benzinga | February 1, 2022

Biofrontera spikes after recruitment update on late-stage trial for skin cancer

Biofrontera <> is trading sharply higher after announcing that the company enrolled 70% of patients in its Phase 3 study for Ameluz photodynamic therapy in superficial basal…

Seeking Alpha | February 1, 2022

Biofrontera, Synaptogenix top healthcare gainers; while Sio Gene, Anavex among losers

Biofrontera (BFRI) +14%. Synaptogenix (SNPX) +11%. Sio Gene Therapies (SIOX) -19%. Anavex Life Sciences (AVXL) -16%.

Seeking Alpha | February 1, 2022

Thinking about buying stock in Ensysce Biosciences, Turkcell Iletisim Hizmetleri A.S., Genocea Biosciences, Inspira Technologies, or Biofrontera?

NEW YORK, Dec. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENSC, TKC, GNCA, IINN, and BFRI. To see how InvestorsObserver''s proprietary scoring system rates these stocks, view the InvestorsObserver''s PriceWatch Alert by selecting the corresponding link.

PR Newswire | December 23, 2021

Biofrontera extends rally to reach a post-IPO peak

No summary available.

Seeking Alpha | December 21, 2021

38 Stocks Moving In Tuesday''s Mid-Day Session

Gainers Reliance Global Group, Inc. (NASDAQ: RELI ) surged 126% to $6.91 after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI ) climbed 71.4% to $13.06 after gaining over 7% on Monday. Biofrontera recently announced the first subject has been enrolled in the Phase 2b study to evaluate the safety and efficacy of Ameluz in combination with the red-light lamp BF-RhodoLED for acne. Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS ) jumped 36% to $3.4550 after the company reported pan-coronavirus monoclonal antibody cocktail that retains effectiveness against the omicron variant, other covid-19 variants, SARS, MERS, and the common cold human coronaviruses. Petros Pharmaceuticals, Inc. (NASDAQ: PTPI ) shares climbed 33.8% to $4.55. Evofem Biosciences, Inc. (NASDAQ: EVFM ) rose 24.1% to...

Benzinga | December 21, 2021

BFRI Stock Alert: The Social Media Chatter That Has Biofrontera Booming Today

Biofrontera (BFRI) stock is on the move today as traders take to Twitter (TWTR) to discuss the latest news surrounding the company.

InvestorPlace | December 21, 2021

Thinking about buying stock in Quoin Pharmaceuticals, Aridis Pharmaceuticals, Biofrontera, Cassava Sciences, or Embraer SA?

NEW YORK , Dec. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for QNRX, ARDS, BFRI, SAVA, and ERJ. Full story available on

Benzinga | December 21, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!